Strategic Initiative

Slingshot members are tracking this corporate initiative:

Lexicon Pharma (LXRX) Acquires Exclusive Research Rights from Bristol-Myers Squibb (BMY) for Neuropathic Pain Candidate LX9211

Source Link:
http://www.nasdaq.com/press-release/lexicon-pharmaceuticals-acquires-exclusive-rights-to-development-candidate-for-neuropathic-pain-20161107-00260

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
BMY
100%
LXRX
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Strategic Initiative Date
Announcement Date:
Nov 07, 2016
Projected Implementation:
Q4, 2016
Relevance Tracked Until:
Q4, 2018
Related Projects Image

  • Don’t see a project related to the strategic initiative you care about?

Related Keywords Exclusive Research Rights, Neuropathic Pain, Lx9211
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.